文献速递脑血管病

WAKE-UP 试验中伴白质高信号患者的静脉溶栓

Intravenous Thrombolysis in Patients With White Matter Hyperintensities in the WAKE-UP Trial.
PubMed 文献 · Stroke · 2023-05-25

该研究为 WAKE-UP 随机试验的事后观察性队列分析,在 441 例发病时间未知的缺血性卒中患者中量化基线白质高信号(WMH)体积,评估 WMH 负荷对静脉阿替普酶溶栓疗效与安全性的影响;WMH 负荷与更差功能结局相关,但与治疗效应或出血转化风险无交互作用。

要点

  • WMH 负荷与 90 天功能结局独立相关(OR 0.72,95%CI 0.57-0.92),但与任何出血转化无显著关联(OR 0.78,95%CI 0.60-1.01)。
  • WMH 负荷与治疗组在优良结局(P=0.443)或任何出血转化(P=0.151)上均无交互作用。
  • 在 166 例严重 WMH 亚组中,静脉溶栓与更高优良结局几率相关(OR 2.40,95%CI 1.19-4.84),出血转化率无显著增加(OR 1.96,95%CI 0.80-4.81)。

核心结论

  • 尽管 WMH 负荷与更差功能结局相关,但在发病时间未知的缺血性卒中患者中,其与静脉溶栓的治疗效应或安全性无关联。

研究设计与样本

  • WAKE-UP 随机试验的事后观察性队列二次分析,503 例随机患者中 441 例扫描质量足以勾画 WMH。
  • 在基线液体衰减反转恢复序列上量化 WMH 体积,患者随机接受阿替普酶或安慰剂。
  • 优良结局定义为 90 天后改良 Rankin 量表评分 0-1 分;出血转化在随机化后 24-36 小时随访影像上评估。
  • 采用多变量逻辑回归模型分析治疗效应与安全性。

主要发现

  • 中位年龄 68 岁,151 例为女性,222 例被分配接受阿替普酶,中位 WMH 体积为 11.4 mL。
  • 独立于治疗,WMH 负荷与更差功能结局显著相关(OR 0.72,95%CI 0.57-0.92),但与任何出血转化几率升高无显著关联(OR 0.78,95%CI 0.60-1.01)。
  • WMH 负荷与治疗组在优良结局可能性(P=0.443)或任何出血转化(P=0.151)上无交互作用。
  • 在 166 例严重 WMH 亚组中,静脉溶栓与更高优良结局几率相关(OR 2.40,95%CI 1.19-4.84),出血转化率无显著增加(OR 1.96,95%CI 0.80-4.81)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: White matter hyperintensities of presumed vascular origin (WMH) are the most prominent imaging feature of cerebral small vessel disease (cSVD). Previous studies suggest a link between cSVD burden and intracerebral hemorrhage and worse functional outcome after thrombolysis in acute ischemic stroke. We aimed to determine the impact of WMH burden on efficacy and safety of thrombolysis in the MRI-based randomized controlled WAKE-UP trial of intravenous alteplase in unknown onset stroke. METHODS: The design of this post hoc study was an observational cohort design of a secondary analysis of a randomized trial. WMH volume was quantified on baseline fluid-attenuated inversion recovery images of patients randomized to either alteplase or placebo in the WAKE-UP trial. Excellent outcome was defined as score of 0-1 on the modified Rankin Scale after 90 days. Hemorrhagic transformation was assessed on follow-up imaging 24-36 hours after randomization. Treatment effect and safety were analyzed by fitting multivariable logistic regression models. RESULTS: Quality of scans was sufficient in 441 of 503 randomized patients to delineate WMH. Median age was 68 years, 151 patients were female, and 222 patients were assigned to receive alteplase. Median WMH volume was 11.4 mL. Independent from treatment, WMH burden was statistically significantly associated with worse functional outcome (odds ratio, 0.72 [95% CI, 0.57-0.92]), but not with higher chances of any hemorrhagic transformation (odds ratio, 0.78 [95% CI, 0.60-1.01]). There was no interaction of WMH burden and treatment group for the likelihood of excellent outcome (P=0.443) or any hemorrhagic transformation (P=0.151). In a subgroup of 166 patients with severe WMH, intravenous thrombolysis was associated with higher odds of excellent outcome (odds ratio, 2.40 [95% CI, 1.19-4.84]) with no significant increase in the rate of hemorrhagic transformation (odds ratio, 1.96 [95% CI, 0.80-4.81]). CONCLUSIONS: Although WMH burden is associated with worse functional outcome, there is no association with treatment effect or safety of intravenous thrombolysis in patients with ischemic stroke of unknown onset. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT01525290.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Frey BM, Shenas F, Boutitie F, et al. Intravenous Thrombolysis in Patients With White Matter Hyperintensities in the WAKE-UP Trial. Stroke. 2023. PMID: 37226772. doi:10.1161/STROKEAHA.122.040247

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。